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Rationale: The development of chronic obstructive pulmonary disease (COPD) in smokers
and their susceptibility to infections is not fully understood. Recent evidences suggest that
Clara cells play a part in host defense, immunomodulatory response and airways
remodelling through the production of speciﬁc factors such as Clara cell 16 (CC-16). This
protein has never been related to patients’ lung function tests, blood gases parameters
and diseases severity.
Objectives: To evaluate a possible correlation between CC-16 expression in sputum,
measured by a new methodological approach, and the degree of severity in patients with
moderate and severe COPD. We also analyzed possible correlations between CC-16 and
cytological sputum population, arterial blood gases and lung function.
Main Findings: We analyzed 20 patients, mean age 72.95, classiﬁed on the basis of the
global initiative for chronic obstructive lung disease guidelines (GOLD 2006). The samples
were processed for cytological analysis and CC-16 levels were assessed by Western blot. We
found lower levels of CC-16 in severe COPD compared to moderate ones (po0.027). No
statistically signiﬁcant differences were found between CC-16 expression and sputum
cellularity (except for macrophages), arterial blood gases, and spirometric parameters.
Multiple linear regression analysis of CC-16 versus functional and cytological parameters
showed no signiﬁcance.
Conclusions: We found a signiﬁcantly different expression of CC-16 in COPD patients,
according to their stage of severity, as deﬁned by the GOLD 2006 guidelines. Considering
CC-16 properties in innate immunity, a possible link between protein expression, innatePublished by Elsevier Ltd.
e local ethical committee.
5553524.
e.it (F. Braido).
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investigation are needed.
& 2007 Published by Elsevier Ltd.Introduction
Chronic obstructive pulmonary disease (COPD) is one of the
major causes of morbidity and mortality among respiratory
diseases and is characterized by an airﬂow limitation that is
not fully reversible. Airﬂow limitation is usually both
progressive and associated with an abnormal inﬂammatory
response of the lung to noxious particles or gases. Many
structural changes can be seen in COPD lung: increased
mucus secretion, airway remodelling, and loss of elastic
recoil with emphysema, the latter two constituting the main
mechanisms of irreversible airway obstruction in severe
COPD.1,2
Two kinds of risk factors are recognized in COPD
pathogenesis. Host factors include genetic pattern, airway
hyperresponsiveness, and lung growth, while environmental
factors include exposure to tobacco smoke, occupational
dusts and chemicals, infections, and socioeconomic status.
Although cigarette smoking is considered the major risk
factor for COPD, only a small rate (10–15%) of smokers
develop the disease, suggesting that a relationship between
environmental and host immunological factors might be
critical in its pathogenesis.
At present there is no test available that predicts
susceptibility to the disease, which is often diagnosed late
in its course; moreover, even though neutrophilic and
lymphocytic inﬁltration are associated with FEV1 decline,
the relationship between immune system and structural
airway changes remains unclear.3,4 However, The National
Heart, Lung, and Blood Institute and the World Health
Organization developed the global initiative for chronic
obstructive lung disease (GOLD) which produced evidence-
based guidelines describing four stages of COPD severity for
worldwide use in its detection and treatment. These four
stages are classiﬁed as mild (I), moderate (II), severe (III),
and very severe (IV).5
COPD pathogenesis involves the peripheral airways, and
pathologic changes seen in the lung samples of COPD
patients include bronchial and bronchiolar obstruction,
mucosal oedema, goblet cells hyperplasia, collagen deposi-
tion and injury of epithelial airway cells.6
Clara cells, namely located in the terminal bronchioles,
are one the most multifunctional epithelial cell types in
mammalian lungs. They appear to be devoted to the
protection of the respiratory tract from inhaled toxic
agents. Indeed, Clara cells repair damaged epithelium,
detoxify xenobiotics, and secrete proteins with important
biological activities such as leukocyte-protease inhibitors
and the 16 kDa Clara cell protein (CC-16).7,8
CC-16 is a non glycoprotein with a molecular mass of
16 kDa, which is produced by Clara cells in the lung and
mucosal epithelial cells in uterus and prostate. Structurally
it is a homodimer of subunits of 70 amino acids covalently
bound in an antiparallel manner9 and one of the main
secretory proteins of the lung. It can be found in highconcentrations in the epithelial lining ﬂuid where it appears
to play an antioxidant/inﬂammatory role by modulating the
production and/or activity of phospholipase-A2, interferon-
g, and tumour necrosis factor a.10 From a diagnostic point of
view, CC-16 could be the fulcrum for a novel approach for
assessing the integrity of respiratory epithelium. Bernard
and colleagues showed a signiﬁcant reduction of CC-16 in
bronchoalveolar lavage of smokers and COPD patients
compared with healthy subjects and hypothesized that this
protein might serve as a sensitive indicator of nonciliated
bronchial cell dysfunction.11 The function of this protein, so
far elucidated, is immunoregulatory and anti-inﬂammatory
in innate immunity. It has been demonstrated that knockout
mice of UG gene resulted in aggravation of inﬂammation
triggered by allergic and hyperoxic stimuli, that could be
represented by viral/bacterial infection or by exposure to
noxious particles.12 Recent evidences conﬁrm and strength-
en the hypothesis that CC-16 protects the respiratory tract
against oxidative stress and inﬂammation.13 A weaker
airways immunity could be caused by reduced levels of this
protein and could confer a lack of protection against viral
and bacterial infection and environmental pollutants. This
could eventually lead to the fact that COPD patients with
lower levels of CC-16 are more prone to develop exacerba-
tions, and consequently suffer from more severe forms of
COPD and vice versa.
Lung samples or BAL from COPD patients show a decrease
in CC-16,14,15 but no spontaneous sputum study has been
performed to investigate the potential correlation between
the level of this protein and the patient’s lung function
tests, sputum cellularity and arterial blood gases.
Aim of the study
The aims of the present study were: to identify a possible different expression of CC-16 in
spontaneous sputum in moderate and severe COPD
patients, to investigate possible correlations between CC-16 levels
and sputum cellularity, arterial blood gases and lung
function.
Methods
Patients population
About 20 COPD patients were enrolled. All the patients were
hospitalized for COPD exacerbation and classiﬁed according
to GOLD 2006 guidelines. Blood gas analysis and spontaneous
sputum collection were performed for each patient (Table 1).
None of them had undergone any systemic steroid therapy
for at least 1-month prior or was suffering from any
malignant neoplasm. Patients have been treated with
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Table 1 Patients’ demographic and clinical/investigational data.
Patient Sex Age Stage FEV1 TI PO2 PCO2 OD %Neu %Eos %Macr %Linf
R-A M 64 Moderate 50 36 83 39 0.13 77 3 18 2
I-S M 77 Moderate 59 52 75 37 0.49 70 2 25 3
P-A M 61 Moderate 60 69 73 38 0.07 49 1 47 3
S-A M 62 Moderate 70 65 75 40 0.11 71 1 28 0
C-L M 79 Moderate 60 69 78 39 0.13 98 0 2 0
L-F M 57 Moderate 64 64 69 37 0.10 90 2 7 1
G-A M 69 Moderate 52 48 60 43 0.24 86 1 8 5
C-M M 69 Moderate 67 62 67 35 0.10 92 2 2 4
P-F M 72 Moderate 48 63 63 44 0.50 78 1 21 0
V-E M 84 Moderate 60 46 73 45 0.22 92 1 6 1
M-M M 86 Moderate 54 40 76 34 0.10 94 0 0 6
A-A M 71 Severe 32 50 55 50 0.22 81 2 15 2
F-C M 73 Severe 38 51 74 64 NA NA NA NA NA
B-F M 68 Severe 48 45 55 47 0.10 94 0 6 0
P-O M 80 Severe 40 50 41 37 NA NA NA NA NA
DN-A M 54 Severe 35 43 56 50 0.17 97 0 3 0
F-G M 81 Severe 43 56 56 46 0.09 92 0 6 2
R-F F 85 Severe 38 40 58 54 0.07 96 0 4 0
A-S M 86 Severe 45 68 55 36 0.07 63 0 10 27
C-C M 81 Severe 45 48 52 53 0.09 NA NA NA NA
G-S M 76 Severe 24 50 73 33 0.06 92 0 8 0
M-A M 70 Severe 35 60 50 60 0.10 93 0 6 1
Patients characteristics: n 10 stage III and n 11 stage IV, according to GOLD guidelines 2006.
TI ¼ Tiffenau index (FEV1/FVC); PO2 arterial partial pressure (tension) of O2 mmHg; CO2 arterial partial pressure (tension) of CO2
mmHg; NA ¼ Not available.
Clara cell 16 protein in COPD sputum 2121inhaled long-acting b2 agonists (formoterol or salmeterol)
and theophylline.
Methods
Each sample of sputum was inserted in a centrifuge tube and
overlaid with an equal volume of diluted Sputolysin reagent
(Calbiochem, San Diego, CA), mixed on a vortex mixer for
30 s and allowed to stand at 37 1C for 15min. After
incubation the mixture was ﬁltered and centrifuged at
1400 rpm for 15min. About 300 ml of M-PER (PIERCE) and 1 ml
of Protease Inhibitor Cocktail (SIGMA) were added to the
supernatant. The suspension was shaken for 10min and then
centrifuged at 27,000g for 15min. The supernatant was
collected in an Eppendorf tube and stored at 20 1C.
Western blot analysis
Western blot analysis was performed using 15% SDS-PAGE
(BIO-RAD protocol) and marker (BIO-RAD) as control: the gel
was transferred electrophoretically to a nitrocellulose
membrane sheet at 12mA overnight at room temperature.
Western blot analysis was performed on all the sputum
samples for CC-16 detection. A semiquantitative measure of
CC-16 was obtained by means of optical density (OD)
methodology value in all the moderate patients (N ¼ 10)
and in eight severe patients (N ¼ 8). The nitrocellulose
sheet was saturated with 5% milk and subsequently
incubated with polyclonal rabbit anti-human urine protein
1 (Dako, 1:1000 dilution) at room temperature for 3 h withshaking. After washing with buffer, the membrane was
incubated with alkaline phosphatase conjugated secondary
antibody monoclonal anti-rabbit immunoglobulin (Sigma,
1:1000 dilution) for 90min at room temperature with
shaking. Finally, the nitrocellulose membrane was washed
and then incubated with NBT/BCIP (Pierce) diluted in
alkaline buffer for 10min and the reaction was stopped
with distilled water. Quantiﬁcation of CC-16 levels was
performed by computerized densitometry analysis. Protein
concentrations are expressed as OD. OD is deﬁned as the
absorbance of an optical element for a given wavelength l
per unit distance and it is measured in ODU, which are
equivalent to ‘‘Absorbance units’’/cm (AU cm–1).
Cytology analysis
Each sample of sputum was inserted in a centrifuge tube and
overlaid with an equal volume of diluted sputolysin reagent
(calbiochem, San Diego, ca), mixed on a vortex mixer for
30 s and allowed to stand at 37 1C for 15min. After
incubation the mixture was ﬁltered. The slides were
prepared using cytocentrifuge and standard techni-
que(200 ml of ﬂuids—800 rpm for 3min).
Slides were stained with Diff Quik stain to differentiate
between eosinophils, neutrophils, macrophages and lym-
phocytes and were viewed with optic microscope (Olympus
U-SPT). The number of inﬂammatory cells was express as the
percent of cell.16,17
Spirometric tests were conducted according to ATS
guidelines.18
ARTICLE IN PRESS
F. Braido et al.2122The volume of air forcibly exhaled from the point of
maximal inspiration (forced vital capacity, FVC) and the
volume of air exhaled during the ﬁrst second of this
maneuver (forced expiratory volume in 1 s, FEV1) has
been measured, and the ratio of these two measurements
(FEV1/FVC) has been calculated. Spirometry measurementsTable 2 Statistical Correlations among CC-16 optical density,
OD Age FEV1 TI
Age
R 0.038
P 0.881
FEV1
R 0.070 0.123
P 0.781 0.605
TI
R 0.043 0.064 0.370
P 0.866 0.787 0.108
PO2
R 0.186 0.114 0.637b 0.001
P 0.459 0.633 0.003 0.997
PCO2
R 0.117 0.048 0.666b 0.224
P 0.643 0.840 0.001 0.342
%Neu
R 0.371 0.027 0.151 0.278
P 0.142 0.919 0.564 0.280
%Eos
R 0.327 0.389 0.352 0.084
P 0.200 0.123 0.166 0.750
%Macr
R 0.571a 0.225 0.200 0.162
P 0.017 0.386 0.443 0.535
%Lym
R 0.183 0.402 0.066 0.265
P 0.482 0.110 0.802 0.304
aCorrelation is statistically signiﬁcant at 0.05 (2-tailed).
bCorrelation is statistically signiﬁcant at 0.01 (2-tailed).
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Figure 1 CC-16 optical density in spontaneous sputum in
moderate and severe COPD (p40.05).are evaluated by comparison with reference values based on
age, height, sex, and race.19
All statistical analyses were carried out with the SPSS12.0
statistical package. A statistically signiﬁcant cut-off value
was set at po0.05.Results
In our sample 10 patients were stage II and 10 stage III
according to GOLD 2006, aged from 54 to 86 years (mean age
72.9579.44 years), 19 male and 1 female, all were former
smokers.
We found signiﬁcantly lower levels of CC-16 in severe
COPD patients as compared to moderate ones (p ¼ 0.027
Mann Whitney test) (Fig. 1). The laboratory method used to
identify and obtain a semi-quantitative value of CC-16 was
reliable and reproducible. Cytological analysis showed no
signiﬁcant difference in cell populations between the two
groups of patients, although there was an increasing trend in
neutrophils in severe as compared to moderate COPD
(p ¼ ns Mann Whitney test). The percentage of neutrophils
out of 500 cells was 81.5% in moderate COPD while in severe
COPD it was 88.2%.
In the entire sample no Pearson correlation was found
between OD and age, FEV1, IT, PO2, PCO2, neutrophils,age, lung function, arterial blood gases, sputum cytology.
PO2 PO2 %Neu %Eos %Macr
0.302
0.196
0.151 0.377
0.564 0.136
0.481 0.368 0.397
0.051 0.146 0.114
0.274 0.146 0.807b 0.503a
0.287 0.575 0.000 0.040
0.184 0.381 0.546a 0.154 0.047
0.479 0.131 0.023 0.556 0.859
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found between OD and macrophages (Table 2).
From the correlation results, some necessary precondi-
tions emerged to deepen the research trying to give an
interpretation and a causal sense to the variables investi-
gated, by means of a multiple regression analysis. Our main
speciﬁc purpose was to identify the parameter that could
predict the OD variable. This is the reason why two multiple
linear regressions (stepwise method) were made in which OD
was considered as dependent variable. In the ﬁrst regression
FEV1, PO2 and PCO2 represented the independent variables,
but the result was not signiﬁcant. In the second one,
neutrophils, macrophages, eosinophils and lymphocytes
represented the independent variables. Even in this
case the results were not signiﬁcant. As a consequence,
FEV1, PO2, PCO2, neutrophils, macrophages, eosinophils,
and lymphocytes do not seem to be able to inﬂuence
OD values.Discussion and conclusions
Recent evidence in mice demonstrate that there is a marked
decrease in the synthesis and secretion of CC-16 during LPS-
induced acute lung inﬂammation and that CC-16 deﬁciency
is associated with increased lung susceptibility to viral
infections and oxidative stress.20,21
In a previous study on BAL of patients at risk for ARDS,
CC-16 concentration was inversely correlated with the
amount of elastase and a decrease in its concentration
was associated with an increase in neutrophil-mediated lung
damage, indicating the likelihood of its acting as a natural
neutrophils inhibitor.22 Thus, a decrease in CC-16 might
contribute to inﬂammatory metaplastic transformation
in the peripheral respiratory tract and could play a
role, via loss of regulatory control, in the cascade of
events which leads to remodelling and irreversible airway
obstruction.
CC-16 has two important modulatory functions: (1)
modulation of surfactant metabolism, in which SP-A
determines secretion and reuptake,23 and CC-16 potentially
inhibits of PLA2-mediated fatty acid release and lysopho-
sphatidylcoline formation24; and (2) modulation of cycloox-
ygenase and lipooxygenase pathways with control over the
production of lipid mediators such as platelet activating
factor and leukotriene B4 by the inhibition of PLA2
activity.25–28
The present study was designed to evaluate CC-16 levels
in the airways of moderate and severe COPD patients and
evaluate possible correlations of this protein with cellular
sputum population and arterial blood gases and lung
function.
We found signiﬁcantly lower levels of CC-16 in severe
COPD patients as compared to moderate ones, demonstrat-
ing a signiﬁcant different expression of protein between
different GOLD stages of COPD. A decrease in CC-16 in the
sputum of COPD patients could reﬂect inﬂammation of the
lower airways and may contribute to progressive anatomic
damage typical of the different COPD stages.8 A previous
study by Bernard found lower level of CC-16 in BAL in COPD
patients.29 Ekberg–Jansson demonstrated that healthy
smokers had a relative high level of CC-16 in the airwaysand this was interpreted as the reason for not developing
COPD.30 We could therefore hypothesize that lower levels of
CC-16 could contribute to ﬁbroblast activation, airway
remodelling and frequent viral and bacterial infections.
The same study on neutrophil associated activation markers,
using a multiple regression analysis, showed that CC-16, an
indicator of Clara cell activity, was one of the factors
inﬂuencing a decrease of lung diffusion CO capacity (DLCO)
independently from smoking habit.30
Our results suggest that despite a different expression of
CC-16 according to GOLD COPD classiﬁcation of severity, the
level of this protein seems to be independent from single
functional (FEV1, FVC, PO2, PCO2) and cytological (sputum
neutrophils, macrophages, lymphocytes and eosinophils)
parameters. Even the multiple regression analysis per-
formed considering functional and cytological parameter
altogether as independent variable showed lack of signiﬁ-
cance.
This observation could be relevant and some explanations
could be suggested. In fact it is quite unlikely to think that
the most abundant secretory protein of the bronchial
district, with emergent physiological functions, is not
involved and related directly or indirectly in the impair-
ments caused by COPD in the lung.
The lack of correlation between CC-16 and the functional
parameters could be explained by the fact that we only
considered FEV1 and TI values, and a correlation could be
found with other values, such as hyperinﬂation index (TLC,
RV), or with parameters reﬂecting a membrane impairment
(DLCO).
Even a correlation with cellularity is missing, but maybe
other markers of inﬂammation could be linked to the levels
of CC-16 (LPS-binding peptide, MPO, Lysozyme, and so on).
Another intriguing possibility could be that CC-16 is
totally independent from function and inﬂammation but
related to the relationship between innate immunity and
infective exacerbation of COPD. In other words, a deﬁcit of
this protein may be indirectly related to severity through a
progressive worsening due to repeated infectious events.
Further investigations are needed to explore if CC-16
could be a valid biomarker for monitoring peripheral airway
damage and if it could be potentially investigated as a
predictor of early lung functional dysfunction and of
predisposition to COPD infective exacerbations. Clinical
and functional parameters, although simple and useful tools
for diagnosis and treatment of COPD, are not good
predictors of tissue damage and functioning, which so far
has only been evaluated with invasive procedures such as
BAL or lung biopsy.26–28 The determination of CC-16 levels in
spontaneous sputum of COPD patients, instead, is non
invasive, easy to perform and reliable. In fact its dosage
could indicate the degree of terminal bronchiolus damage
and susceptibility to diseases worsening. Anyway, further
investigations are needed to elucidate its clinical and
pathogenetical signiﬁcance and the existing correlations
with COPD markers, as these aspects were not identiﬁed by
our study, mainly due to the small sample size and the
chosen parameters.
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